NCT05607017CompletedEarly phase 1
Losartan in Prevention of Radiation-Induced Heart Failure
The Role of Losartan in the Prevention of Early Structural Changes Associated With Radiation-Induced Heart Failure
Source: ClinicalTrials.gov · Last updated 6 Apr 2026
Brief summary (registry, in English)
This study is being done to see if losartan affects the chances of developing radiation-induced heart failure in patients who are receiving radiation therapy as part of standard of care treatment for breast cancer. The interventions involved in this study are: * Losartan * Radiation Therapy (standard of care)
- Status (registry)
- Completed
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- First submitted
- 1 Nov 2022
- Start date
- 13 Sept 2023
- Primary completion date
- 7 Oct 2025
- Lead sponsor
- Massachusetts General Hospital
- Diseases
- Heart failure
- NCT number
- NCT05607017
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 5
- From 13 Sept 2023 to the primary completion date, 7 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient unable to swallow oral medication.
- Patients receiving any other investigational agent will not be excluded from study eligibility, unless the patient is already enrolled in an interventional study evaluating cardiac toxicity
- Patients already receiving ACE/ARBs.
Other illness
- Patients with a history of allergic reactions to Losartan biosimilars.
Other
- Person who is pregnant or breastfeeding.
Who the study is looking for
- -\>18 years of age
- Non-metastatic Breast Cancer patients who are scheduled to receive conventional left breast/chest wall RT inclusive of treatment to the internal mammary lymph nodes (IMNs)
- Prior chemotherapy is permitted
- Patients must have Left-sided Breast Cancer
- Ability to understand and the willingness to sign a written informed consent document
- No contraindication to MRI
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Massachusetts General Hospital Cancer Center Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.